---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-296201"
form_type: "8-K"
ticker: "RXST"
cik: "0001111485"
company_name: "RxSight, Inc."
filed_at: "2026-07-06T20:15:17+00:00"
generated_at: "2026-07-06T20:16:08.148985+00:00"
event_type: "m_and_a"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# RxSight and Alcon enter collaboration to develop adjustable PCIOLs; $60M upfront, up to $140M milestones

## Summary
- RxSight receives $60M upfront; potential $70M feasibility milestone, $30M FDA submission milestone, $40M approval milestone.
- Alcon to pay 30% royalties on net sales of collaboration products; RxSight to develop and manufacture, Alcon to commercialize globally.
- Collaboration combines RxSight's light-adjustable technology with Alcon's presbyopia-correcting IOL optics for post-operative fine-tuning.
- Agreement includes non-exclusive licenses; RxSight retains U.S. regulatory approvals and will supply LDD devices.
- Deal could accelerate adoption of adjustable IOLs; Alcon is global eye care leader (SIX/NYSE: ALC).

## SEC filing metadata
- accession: 0001193125-26-296201
- form_type: 8-K
- ticker: RXST
- cik: 0001111485
- company_name: RxSight, Inc.
- filed_at: 2026-07-06T20:15:17+00:00
- event_type: m_and_a
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 1.01, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1111485/000119312526296201/0001193125-26-296201-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1111485/000119312526296201/rxst-20260630.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-296201
- JSON: https://secwatch.observer/filing/0001193125-26-296201.json
- Plain text: https://secwatch.observer/filing/0001193125-26-296201.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.